iBio Inc (IBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31+0.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating losses and cash burn: FY26 operating loss -35141.0% vs target -8.37M.
iBio plans to start clinical trial dosing in 2Q 2026. The company aims to manage losses and cash burn while developing programs. Analysts expect revenue near zero in 2026 but see potential growth later.
iBio is losing money and burning cash with no profit progress. Revenue is expected to fall 72% next year. Recent leadership changes and litigation add risks.
The market expects about a 72% drop in revenue next year. Our fair value matches the consensus price of $0.43, reflecting high risk and low growth.
Breaks if: Dosing not initiated by end of 2Q 2026
Breaks if: Operating loss exceeds negative $8.37 million in 2026-Q3
Revenue decline exceeds 72% in next 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it is focused on advancing its clinical trials and expanding its pipeline.
The market appears to have low expectations for IBIO, as indicated by a low expectations gap. However, it is trading at a premium compared to its peers, suggesting that some level of optimism is already priced in despite its current financial struggles.
Recent financial performance has been weak, and there is a significant probability of missing estimates in the near term. However, management has made consistent progress in clinical trials, which may provide some support for future performance.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the overall healthcare sector momentum. If sector leaders continue to perform well, it could positively impact IBIO, while any negative guidance or economic downturns could have adverse effects.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has weakened. The latest earnings report missed expectations significantly. This miss raises concerns about the company's financial health. There are no new supportive factors to offset this weakness. The overall market backdrop remains challenging for growth stocks like IBIO.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, IBIO's future will depend on its ability to execute on clinical milestones and navigate market conditions. Not investment advice.